Targeted therapy using alpha emitters

Physics in Medicine and Biology

Volumn 41, Issue 10, 1996, Pages 1915-1931

  Vaidyanathan, Ganesan ^a   Zalutsky, Michael R ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA RADIATION; ARTICLE; CANCER RADIOTHERAPY; LINEAR ENERGY TRANSFER; METASTASIS; PRIORITY JOURNAL;

EID: 0029784810     PISSN: 00319155     EISSN: None     Source Type: Journal    
DOI: 10.1088/0031-9155/41/10/005     Document Type: Article

References (71)

1. Aaij C, Tschroots W R J M, Lindner L and Feltkamp T E W 1975 The preparation of astatine labelled proteins Int. J. Appl. Radiat. Isotopes 26 25-30
2. 224Ra Appl. Radiat. Isotopes 39 282-6
3. 90Y Int. J. Radiat. Oncol. Biol. 10 341-8
4. Brenner D J 1992 Radon: current challenges in cellular radiobiology Int. J. Radiat. Biol. 61 3-13
5. 211At-astato-2-methyl-1,4-naphthoquinol bis (disodium phosphate): a novel α-emitting potential anti-tumour drug Int. J. Appl. Radiat. Isotopes 33 75-6
6. - in mice with a transplanted rectal adenocarcinoma Int. J. Appl. Radiat. Isotopes 35 843-7
7. 211At]-astatinated endoradiotherapeutic drug: part I. Localization by α-particle track autoradiography in a murine tumour model Int. J. Radiat. Oncol. Biol. Phys. 23 563-72
8. 211At]-astatinated endoradiotherapeutic drug: part II. Therapeutic results for transplanted adenocarcinoma of the rectum in mice and associated studies Int. J. Radiat. Oncol. Biol. Phys. 29 115-24
9. 125I]iodobenzylguanidine in the human neuroblastoma cell SK-N-SH Cancer Res. 45 6366-70
10. Caraventa A, Guerra P, Arrighini A, Bertolazzi L, Bestagno M, de Bernardi B, Lanino E, Villavecchia G P and Claudiani F 1991 Treatment of advanced neuroblastoma with I-131 meta-iodobenzylguanidine Cancer 67 922-8
11. Casarett G W 1964 Pathology of single intravenous doses of polonium Radiat. Res. Suppl. 5 246-321
12. Friedman A M et al 1977 Preparation of a biologically stable and immunogenically competent astatinated protein Int. J. Nucl. Med. Biol. 4 219-24
13. Gansow O A, Atcher R W, Link D C, Friedman A M, Seevers R H, Anderson W, Scheinberg D A and Strand M 1984 Generator-produced Bi-212: chelated to chemically modified monoclonal antibody for use in radiotherapy Am. Chem. Soc. Symp. Ser. 241 215-27
14. 2 fragment Cancer Res. 50 3514-20
15. Hall E J 1994 Radiobiology for the Radiologist (Philadelphia: Lippincott) pp 153-64
16. Humm J L 1986 Dosimetric aspects of radiolabeled antibodies for tumor therapy J. Nucl. Med. 27 1490-7
17. _1987 A microdosimetric model of astatine-211 labeled antibodies for radioimmunotherapy Int. J. Radiat. Biol. Phys. 13 1767-73
18. Humm J L and Chin L M 1993 A model of cell inactivation by alpha α-particle internal emitters Radiat. Res. 134 143-50
19. Humm J L, Macklis K, Bump K, Cobb L M and Chin L M 1993b Internal dosimetry using data derived from autoradiographs J. Nucl. Med. 34 1811-17
20. Humm J L, Roeske J C, Fisher D R and Chen G T Y 1993a Microdosimetric concepts in radioimmunotherapy Med. Phys. 20 535-41
21. Huneke R B, Pippin C G, Squire R A, Brechbiel M W, Gansow O A and Strand M 1992 Effective α-particle-mediated radioimmunotherapy of murine leukemia Cancer Res. 52 5818-20
22. 211At in small volumes for evaluation of targeted radiotherapy in animal models Nucl. Med. Biol. 22 45-54
23. 212Bi) therapy Cancer Res. 53 5683-9
24. Kampf G 1988 Induction of DNA double-strand breaks by ionizing radiation of different quality and their relevance for cell inactivation Radiobiol. Radiother. 29 631-58
25. Kemshead J T, Pizer P L and Patel K 1990 Neuroblastoma: perspectives for future research Neuroblastoma: Tumor Biology and Therapy ed C Pochedly (Boca Raton, FL: CRC) pp 381-95
26. Kozak R W, Atcher R W, Gansow O A, Friedman A M, Hines J J and Waldman T A 1986 Bismuth-212-labeled anti-Tac monoclonal antibody: α-particle-emitting radionuclides as modalities for radioimmunotherapy Proc. Natl. Acad. Sci. USA 83 474-8
27. 212Bismuth linked to an antipancreatic carcinoma antibody: model for alpha-particle-emitter radioimmunotherapy J. Nat. Cancer Inst. USA 80 449-52
28. 211At-labeling of polymer particles for radiotherapy: synthesis, purification and stability J. Labelled Compound Radiopharm. 33 977-86
29. 211At in a murine intraperiloneal tumor model Gynecol. Oncol. 57 9-15
30. 211At-methylene blue for pigmented melanoma in an animal model system Cancer Res. 49 4332-7
31. 211At-methylene blue for targeted radiotherapy of human melanoma xenografts: treatment of micrometastases Cancer Res. 50 2963-7
32. 211At-methylene blue for targeted radiotherapy of human melanoma xenografts: treatment of cutaneous tumors and lymph node metastases Cancer Res. 52 4385-90
33. Macklis R M, Kaplan W D, Ferrara J L M, Atcher R W, Hines J J, Burakoff S J and Coleman C N 1989 Resident's essay award: alpha particle radio-immunotherapy: animal models and clinical prospects Int. J. Radiat. Oncol. Biol. Phys. 16 1377-87
34. Macklis R M, Kinsey B M, Kassis A I, Ferrara J L M, Atcher R W, Hines J J, Coleman C N, Adelstein S J and Burakoff S J 1988 Radioimmunotherapy with alpha α-particle-emitling immunoconjugates Science 240 1024-6
35. Macklis R M, Lin J Y, Beresford B, Atcher R W, Hines J J and Humm J L 1992 Cellular kinetics, dosimetry, and radiobiology of α-particle radioimmunotherapy: induction of apoptosis Radiat. Res. 130 220-6
36. 131I]meta-iodobenzylguanidine: implications for the targeted radiotherapy of neuroblastoma Eur. J. Cancer A 31 576-81
37. McEwan A J, Wyeth P and Ackery D 1986 Radioiodinated iodobenzylguanidines for diagnosis and therapy Appl. Radiat. Isotopes 37 765-75
38. McLaughlin W H, Thramann A B Jr, Lambrecht R M, Milius R A and Bloomer W D 1988 Preliminary observations of malignant melanoma therapy using radiolabeled alpha methyltyrosine J. Surgical Oncol. 37 192-7
39. Milius R A, McLaughlin W H, Lambrecht R M, Wolf A P, Carroll J J, Adelstein S J and Bloomer W D 1986 Organoastatine chemistry. Astatination via electrophilic destannylation Appl. Radiat. Isotopes 37 799-802
40. O'Donoghue J A 1996 Targeted therapy using auger electron emitters Phys. Med. Biol. 41 1973-92
41. 131I-radiolabelled meta-iodobenzylguanidine (MIBG) for the targeted radiotherapy of neuroblastoma Br. J. Radiol. 64 428-34
42. Ott R J 1996 Imaging technologies for radionuclide dosimetry Phys. Med. Biol. 41 1885-94
43. Roeske J C and Chen G T Y 1991 A dosimetry model for intracavitary radioimmunotherapy of cystic brain tumors Antibody Immunoconj. Radiopharm. 4 637-47
44. Roeske J C, Chen G T Y, Atcher R W, Pelizzari C A, Rotmensch J, Haraf D, Montag A and Weichselbaum R R 1990 Modeling of dose to tumor and normal tissue from intraperitoneal radioimmunotherapy with alpha and beta emitters Int. J. Radiat. Oncol. Biol. Phys. 19 1539-48
45. Rotmensch J, Atcher, R W, Schlenker R, Hines J, Grdina D, Block B S, Press M F, Herbst A L and Weichselbaum R R 1989 The effect of the α-emitting radionuclide lead-212 on human ovarian carcinoma: a potential new form of therapy Gynecol. Oncol. 32 236-9
46. Ruegg C L, Anderson-Berg W T, Brechbiel M W, Mirzadeh S, Gansow O A and Strand M 1990 Improved in vivo stability and tumor targeting of bismuth-labeled antibody Cancer Res. 50 4221-6
47. 131I-MIBG Int. Meeting on MIBG and New Honions in Neuroblastoma Treatment (Westerland/Sylt, April 25-26) Abstract
48. 123I-MIBG Med. Pediatr. Oncol. 15 170-7
49. 131I-metaiodobenzylguanidine Eur. J. Nucl. Med. 14 337-40
50. Sisson J C et al 1990 Iodine-125-MIBG to treat neuroblastoma: preliminary report J. Nucl. Med. 31 1479-85
51. Sisson J C et al 1984 Radiopharmaceutical treatment of malignant pheochromocytoma J. Nucl. Med. 24 197-206
52. Stinchcomb T G and Roeske J C 1992 Analytic microdosimetry for radioimmunotherapeutic alpha emitters Med. Phys. 19 1385-93
53. 211At]astatobenzylguanidine on human neuroblastoma cells Cancer Res. 54 5414-19
54. Turkington T G, Zalutsky M R, Jaszczak, R J, Garg P K, Vaidyanathan G and Coleman R E 1993 Measuring astatine-211 distributions with SPECT Phys. Med. Biol. 38 1121-30
55. 211At]astatobenzylguanidine in an athymic mouse human neuroblastoma xenograft model Nucl. Med. Biol. 23 at press
56. 211At]astato-2′-deoxyuridine, an α-particle-emitting endoradiotherapeutic agent undergoing DNA incorporation Cancer Res. 56 1204-9
57. 211At]astatobenzylguanidine: further evaluation of a potential therapeutic agent Int. J. Cancer 57 908-13
58. 211At]astatobenzyl)guanidine: synthesis via astato demetalation and preliminary in vitro in vivo evaluation Bioconjugate Chem. 3 499-503
59. 131I]iodo-benzylguanidine Appl. Radiat. Isotopes 44 621-8
60. 123I]MIBG: synthesis and preliminary evaluation Nucl. Med. Biol. 22 61-4
61. 211At labelled lectins and antibodies Int. J. Nucl. Med. Biol. 9 167-82
62. 211At labelled monoclonal antibody with known specificity in murine system Int. J. Radiat. Oncol. Biol. Phys. 8 1943-6
63. Vaughan A T M and Fremlin J H 1978 The preparation of astatine labelled proteins using an electrophilic reaction Int. J. Nucl. Med. Biol. 5 229-30
64. 32P colloids in amurine intraperitoneal tumor model Gynecol. Oncol. 47 366-72
65. 90Y) colloids in mice Gynecol. Oncol. 47 358-65
66. Weinreich R, Larsson B, Casteleyn K, Weckermann B, Fischer S, Knust E J, Kumpulainen J and Goldin L L 1994 Establishment of a European astatine collaboration: potentialities and prospects Hadrontherapy in Oncology ed U Amaldi and B Larsson pp 681-6
67. Wieland D M 1986 Radiopharmaceutical design: the adrenal medulla and its diseases Radiopharmaceuticals: Progress and Clinical Perspectives vol 1 ed A R Fritzberg (Boca Raton, FL: CRC) pp 117-53
68. Zalutsky M R and Bigner D D 1996 Radioimmunotherapy with α-particle emitting radio-immunoconjugates Acta Oncol. at press
69. 2 fragments with the alpha particle emitting nuclide astatine-211: preservation of immunoreactivity and in vivo localizing capacity Proc. Natl. Acad. Sci. USA 86 7149-53
70. Zalutsky M R, McLendon R, Garg P K, Archer G E, Schuster J M and Bigner D D 1994 Radioimmunotherapy of neoplastic meningitis in rats using an α-particle-emitting immunoconjugate Cancer Res. 54 4719-25
71. Zalutsky M R and Narula A S 1988 Astatination of proteins using an N-succinimidyl tri-n-butylstannylbenzoate intermediate Appl. Radiat. Isotopes 39 227-32